Cervical high-grade epithelial lesions HSIL combined with high-risk HPV infection
Conditions
Interventions
Photodynamic therapy + CO2 laser therapy group:6 times Photodynamic therapy + 1 time CO2 laser therapy
Photodynamic therapy group:6 times Photodynamic therapy
Sponsors
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Female, Aged 18-45 years; 2. High-risk HPV positive; 3. HSIL (CIN2 and p16+) or HSIL (CIN2, 3 ungraded): within 3 months cervical histopathological examination was CIN2 and immunohistochemical p16 positive, or HSIL (CIN2, 3 ungraded); 4. The squamocolumnar junction is completely visible under colposcopy, the lesions are completely visible, and there is no CIN2+ in the cervical canal scraping pathology; 5. The pregnancy test is negative, and condoms are used for contraception from the end of the last menstrual period to 3 months after the start of the test, or when they agree to have sex; 6. Have the desire to preserve the structure and/or function of the cervix, voluntarily participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Colposcopy cannot rule out the possibility of invasive cancer, or the lesions extend to the vaginal wall; 2. Severe pelvic inflammation, cervical inflammation or other serious gynecological inflammation was found in clinical examination; 3. Those with undiagnosed vaginal bleeding; 4. Those who currently suffer from allergic diseases; those who are suspected or known to suffer from porphyria or known to have a history of allergy to the experimental drugs and their chemical structures similar to drugs; 5. Patients with severe cardiovascular and cerebrovascular, neurological, mental, endocrine, liver function, hematopoietic system diseases; known to be severely weakened in immune function, or who need long-term use of glucocorticoids and immunosuppressants; patients with malignant tumors; 6. Lactating women; 7. Those who have taken physical therapy or surgical treatment after the pathological diagnosis of HSIL; 8. Those who have received interferon and antiviral drugs within 3 months; 9. Those with poor compliance, or those who are expected to be unable to complete the test and follow-up due to restrictions on residence and other conditions; 10. In addition to the above, the investigator judges that they are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| human papillomavirus; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cervical cytology;Colposcopy + pathological biopsy; | — |
Countries
China
Contacts
Public ContactQiu Lihua
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed